BioMarin's Brineura Approval Shows FDA's Open Door For Orphan Drugs

Filing supporting Brineura was supported by a tiny, single-arm study and had no advisory committee review, the latest sign of the US regulatory agency's willingness to speed orphan drugs for serious pediatric diseases.